Longboard Pharmaceuticals (LBPH) Peer Comparison

$59.98

$0.00 (0.00%)

As on 13-Dec-2024 09:30EDT

Market cap

$2,342 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.5

Div. Yield

0 %

Edit

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Market cap ($ Mln)	2,342	38	21
Revenue ($ Mln)	0	2	1
Net Profit ($ Mln)	-76.34	-34.92	-15.95
Net Margin (%)	-954,300.00	-1,583.49	-1,179.96
RoE (%)	-25.93	-312.41	-83.45
Price to Earnings	--	--	--
Price-To-Book	8.51	7.64	1.10

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Operating Revenue	0.01	2.21	1.35
Cost of Revenue	0.00	0.02	5.18
Gross Profit	-0.01	2.05	1.01
Operating Expenses	87.45	38.51	19.48
Operating Profit (EBIT)	-87.45	-36.33	-18.10
Other Income	0.00	0.00	0.00
Profit before Tax	-76.34	-34.92	-15.95
Provision for Tax	-0.61	0.68	-0.77
Profit after Tax (Net Income)	-76.34	-34.92	-15.95
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Shareholder's Funds	275.19	4.91	16.27
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	3.47	6.04	0.00
Current Liabilities	18.35	6.51	4.25
Total Liabilities	50.70	40.64	38.68

Assets ($ Mln)

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Non-Current Assets	3.98	0.19	0.00
Current Assets	293.03	17.27	20.52
Total Assets	50.70	40.64	38.68
Total Debt*	3.73	0.17	0.00
Net Current Assets	0.00	10.77	16.27

Cashflow ($ Mln)

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Cash From Operating Activities	-50.87	-31.10	-53.82
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	30.19	-0.58	19.80
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
ROCE (%)	-105.05	-77.61	-72.41
ROE (%)	-25.93	-312.41	-83.45
ROA (%)	-23.29	-89.72	-28.23
EBIT Margin (%)	-1,093,125.00	-1,302.26	-1,156.14
Net Margin (%)	-954,300.00	-1,583.49	-1,179.96
Cash Profit Margin (%)	-238.58	-0.08	0.04

Growth Ratios

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Revenue Growth (%)	--	26.94	-97.15
EBIT Growth (%)	-65.27	19.03	-1,233.70
Net Profit Growth (%)	-53.16	-10.63	41.27
EPS Growth (%)	5.65	-10.67	--
Book Value Growth (%)	218.79	-86.73	--

Valuation Ratios

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Price / Earnings	-2.65	-0.76	--
Price / Book Value	3.53	0.94	--
Dividend Yield (%)	--	--	--
EV/EBITDA	-1.70	0.27	1.16
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.03	0.00
Current Ratio	15.97	2.66	4.82
Quick Ratio	15.97	2.66	4.82
Interest Coverage	-149.88	-24.34	-2.43

Operating Efficiency Ratios

	Longboard Pharmaceuticals (LBPH)	Lumos Pharma (LUMO)	Pieris Pharmaceuticals (PIRS)
Debtors to sales (%)	0.00	7.89	65.01
Asset Turnover	0.00	0.06	0.02
Receivable days	--	38.56	27.23
Inventory Days	--	--	35.71
Payable days	84,409.28	4,835.41	32.88
Cash Conversion Cycle	--	--	30.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly